| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.
|
Eur J Nucl Med Mol Imaging
|
2010
|
7.82
|
|
2
|
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography.
|
Am J Respir Crit Care Med
|
2015
|
2.93
|
|
3
|
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.
|
Eur J Nucl Med Mol Imaging
|
2014
|
2.79
|
|
4
|
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.
|
Eur J Nucl Med Mol Imaging
|
2009
|
1.68
|
|
5
|
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
|
Eur J Nucl Med Mol Imaging
|
2010
|
1.68
|
|
6
|
EANM/SNMMI guideline for 18F-FDG use in inflammation and infection.
|
J Nucl Med
|
2013
|
1.37
|
|
7
|
EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy.
|
Eur J Nucl Med Mol Imaging
|
2008
|
1.33
|
|
8
|
Sentinel node in breast cancer procedural guidelines.
|
Eur J Nucl Med Mol Imaging
|
2007
|
1.30
|
|
9
|
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.
|
Eur J Nucl Med Mol Imaging
|
2012
|
1.28
|
|
10
|
Assessment of tumor response in malignant pleural mesothelioma.
|
Cancer Treat Rev
|
2007
|
1.21
|
|
11
|
EANM procedure guideline for treatment of refractory metastatic bone pain.
|
Eur J Nucl Med Mol Imaging
|
2008
|
1.18
|
|
12
|
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
|
J Clin Oncol
|
2006
|
1.12
|
|
13
|
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.
|
Eur J Nucl Med Mol Imaging
|
2010
|
1.03
|
|
14
|
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.
|
Br J Haematol
|
2009
|
1.00
|
|
15
|
FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables.
|
Eur J Nucl Med Mol Imaging
|
2008
|
1.00
|
|
16
|
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
|
Haematologica
|
2012
|
1.00
|
|
17
|
131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.99
|
|
18
|
Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study.
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.99
|
|
19
|
A portrait of the scientist as a young woman : comments after the first EANM Young Investigators' meeting.
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.97
|
|
20
|
Surgical procedures in the DANTE trial, a randomized study of lung cancer early detection with spiral computed tomography: comparative analysis in the screening and control arm.
|
J Thorac Oncol
|
2011
|
0.96
|
|
21
|
Clinical use of PET-CT data for radiotherapy planning: what are we looking for?
|
Radiother Oncol
|
2010
|
0.92
|
|
22
|
FDG PET/CT predictive role in follicular lymphoma.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.91
|
|
23
|
Somatostatin receptor SPECT.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.91
|
|
24
|
Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review.
|
Crit Rev Oncol Hematol
|
2013
|
0.90
|
|
25
|
18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR.
|
Clin Nucl Med
|
2012
|
0.89
|
|
26
|
Molecular imaging in radiotherapy planning for head and neck tumors.
|
J Nucl Med
|
2011
|
0.86
|
|
27
|
Metastatic gastric cancer presenting with shoulder-hand syndrome: a case report.
|
J Med Case Rep
|
2008
|
0.81
|
|
28
|
Imaging biomarkers in primary brain tumours.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.80
|
|
29
|
Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
|
Tumori
|
2011
|
0.80
|
|
30
|
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
|
Nucl Med Rev Cent East Eur
|
2007
|
0.80
|
|
31
|
Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma.
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.80
|
|
32
|
Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors.
|
Tumori
|
2015
|
0.79
|
|
33
|
Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.79
|
|
34
|
[11C]-choline PET/CT in imaging locally advanced prostate cancer.
|
Nucl Med Rev Cent East Eur
|
2011
|
0.79
|
|
35
|
Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers < or =2 cm.
|
Endocr Relat Cancer
|
2008
|
0.79
|
|
36
|
PET in radiotherapy planning: particularly exquisite test or pending and experimental tool?
|
Radiother Oncol
|
2010
|
0.79
|
|
37
|
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.79
|
|
38
|
Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study.
|
Med Sci Monit
|
2012
|
0.78
|
|
39
|
Cardiac and acoustic metastases in relapsing melanoma.
|
Clin Nucl Med
|
2013
|
0.78
|
|
40
|
Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide.
|
Eur J Endocrinol
|
2003
|
0.78
|
|
41
|
What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients?
|
Acta Oncol
|
2014
|
0.78
|
|
42
|
What impact can fluorine-18 fluorodeoxyglucose PET/computed tomography have on HIV/AIDS and tuberculosis pandemic?
|
Nucl Med Commun
|
2009
|
0.78
|
|
43
|
Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings.
|
Microvasc Res
|
2010
|
0.78
|
|
44
|
Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.77
|
|
45
|
Feasibility of carbidopa premedication in pediatric patients: a pilot study.
|
Cancer Biother Radiopharm
|
2012
|
0.77
|
|
46
|
11C-labeled methionine and evaluation of malignant pleural mesothelioma.
|
N Engl J Med
|
2007
|
0.77
|
|
47
|
Somatostatin receptor scintigraphy for bronchial carcinoid follow-up.
|
Clin Nucl Med
|
2003
|
0.76
|
|
48
|
Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion.
|
Eur J Nucl Med Mol Imaging
|
2004
|
0.76
|
|
49
|
The rising PET: the increasing use of choline PET/CT in prostate cancer.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.76
|
|
50
|
SNMMI/EANM guideline for guideline development 6.0.
|
J Nucl Med Technol
|
2012
|
0.75
|
|
51
|
Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
|
Eur Urol
|
2011
|
0.75
|
|
52
|
Evaluation of response: is 18F-FDG PET the answer?
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.75
|
|
53
|
Reply to comment on Pepe et al.: Somatostatin receptor SPECT.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.75
|
|
54
|
Imaging struma ovarii by means of 124I-Na PET/CT.
|
Nucl Med Rev Cent East Eur
|
2013
|
0.75
|
|
55
|
Why New Journals? The Growth of the EJNMMI Family.
|
Eur J Nucl Med Mol Imaging
|
2015
|
0.75
|
|
56
|
Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.
|
Eur J Nucl Med Mol Imaging
|
2015
|
0.75
|
|
57
|
Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
|
J Endocrinol Invest
|
2014
|
0.75
|
|
58
|
A case of atypical giant cell arteritis diagnosed by positron emission tomography (PET).
|
Clin Rheumatol
|
2008
|
0.75
|
|
59
|
Radioiodine treatment of non-toxic multinodular goitre: effects of combination with lithium.
|
Eur J Nucl Med Mol Imaging
|
2005
|
0.75
|
|
60
|
Imaging acute spinal myelitis with 18F-FDG PET/CT.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.75
|
|
61
|
Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion.
|
Nucl Med Commun
|
2017
|
0.75
|
|
62
|
Cerebral Proliferative Angiopathy (CPA): Imaging Findings and Response to Therapy.
|
Clin Nucl Med
|
2016
|
0.75
|
|
63
|
Shaping our future.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.75
|
|
64
|
Isotopic biomarker discovery and application in translational medicine.
|
Drug Discov Today
|
2009
|
0.75
|